These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12893206)

  • 21. Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma.
    Scarabelli C; Gallo A; Franceschi S; Campagnutta E; De G; Giorda G; Visentin MC; Carbone A
    Cancer; 2000 Jan; 88(2):389-97. PubMed ID: 10640973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis.
    Chang SJ; Hodeib M; Chang J; Bristow RE
    Gynecol Oncol; 2013 Sep; 130(3):493-8. PubMed ID: 23747291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later?
    Gonzalez Bayon L; Steiner MA; Vasquez Jimenez W; Asencio JM; Alvarez de Sierra P; Atahualpa Arenas F; Rodriguez del Campo J; Garcia Sabrido JL
    Eur J Surg Oncol; 2013 Oct; 39(10):1109-15. PubMed ID: 23870278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.
    Lim MC; Yoo HJ; Song YJ; Seo SS; Kang S; Kim SH; Yoo CW; Park SY
    J Gynecol Oncol; 2017 Jul; 28(4):e48. PubMed ID: 28541636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. "Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary.
    Eisenkop SM; Spirtos NM; Lin WC
    Gynecol Oncol; 2006 Oct; 103(1):329-35. PubMed ID: 16876853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
    Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
    Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Douglas peritonectomy compared to recto-sigmoid resection in optimally cytoreduced advanced ovarian cancer patients: analysis of morbidity and oncological outcome.
    Gallotta V; Fanfani F; Vizzielli G; Panico G; Rossitto C; Gagliardi ML; Margariti PA; Salerno MG; Zannoni GF; Pacelli F; Scambia G; Fagotti A
    Eur J Surg Oncol; 2011 Dec; 37(12):1085-92. PubMed ID: 21945640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.
    Fotiou S; Aliki T; Petros Z; Ioanna S; Konstantinos V; Vasiliki M; George C
    Gynecol Oncol; 2009 Aug; 114(2):178-82. PubMed ID: 19450872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer.
    Eisenkop SM; Spirtos NM; Lin WC
    Gynecol Oncol; 2006 Feb; 100(2):344-8. PubMed ID: 16202446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer].
    Yan X; An N; Jiang GQ; Gao M; Gao YN
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):298-301. PubMed ID: 18788637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study.
    Massari R; Barone M; Basilico R; Carella C; Colasante A; De Tursi M; Filippone A; Guetti L; Mani A
    Minerva Chir; 2014 Feb; 69(1):17-26. PubMed ID: 24675243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum.
    Look M; Chang D; Sugarbaker PH
    Int J Gynecol Cancer; 2003; 13(6):764-70. PubMed ID: 14675312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer - a prospective nation-wide study in Finland.
    Kumpulainen S; Sankila R; Leminen A; Kuoppala T; Komulainen M; Puistola U; Hurme S; Hiekkanen H; Mäkinen J; Grénman S
    Gynecol Oncol; 2009 Nov; 115(2):199-203. PubMed ID: 19695688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complete cytoreduction: is epithelial ovarian cancer confined to the pelvis biologically different from bulky abdominal disease?
    Naik R; Nordin A; Cross PA; Hemming D; de Barros Lopes A; Monaghan JM
    Gynecol Oncol; 2000 Aug; 78(2):176-80. PubMed ID: 10926799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.
    Eisenkop SM; Friedman RL; Spirtos NM
    Cancer; 2000 Jan; 88(1):144-53. PubMed ID: 10618617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
    Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
    J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
    Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
    Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
    Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q
    Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data.
    Polterauer S; Vergote I; Concin N; Braicu I; Chekerov R; Mahner S; Woelber L; Cadron I; Van Gorp T; Zeillinger R; Castillo-Tong DC; Sehouli J
    Int J Gynecol Cancer; 2012 Mar; 22(3):380-5. PubMed ID: 22266934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.